Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Up 114.9% in February

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the target of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 63,474 shares, a growth of 114.9% from the January 29th total of 29,530 shares. Based on an average daily volume of 33,865 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.1% of the company’s stock are short sold. Approximately 0.1% of the company’s stock are short sold. Based on an average daily volume of 33,865 shares, the days-to-cover ratio is currently 1.9 days.

Analysts Set New Price Targets

NBTX has been the subject of several analyst reports. TD Cowen assumed coverage on Nanobiotix in a report on Friday, February 6th. They set a “buy” rating for the company. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. Guggenheim raised their price target on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Nanobiotix currently has an average rating of “Moderate Buy” and an average target price of $20.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Optiver Holding B.V. purchased a new position in shares of Nanobiotix during the 3rd quarter valued at approximately $101,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix during the 4th quarter valued at approximately $220,000. Finally, Millennium Management LLC acquired a new position in shares of Nanobiotix in the 4th quarter valued at $390,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.

Nanobiotix Stock Performance

NBTX traded up $3.53 during trading on Friday, reaching $31.04. 86,067 shares of the company’s stock were exchanged, compared to its average volume of 26,320. Nanobiotix has a 1 year low of $2.95 and a 1 year high of $31.62. The company’s fifty day simple moving average is $22.88 and its 200-day simple moving average is $19.32.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.